We focus on small-batch synthesis because it allows for an unflinching level of quality control that's impossible with mass production
The peptides gentle yet effective approach makes it suitable for long-term wellness support
Over the last decade, GLP-1 therapies have transformed diabetes and obesity treatment
To better understand how the field is evolving and where it might go next DDN spoke with Jan Jezek, Chief Scientific Officer at Arecor Therapeutics, about the scientific challenges, delivery innovations, and future opportunities surrounding GLP-1 therapies
This allows it to bypass harsh digestive conditions and slip through the gut wall more efficiently, landing directly in your bloodstream
An origin from degenerate mitochondria, endoplasmic reticulum and glycogen has been suggested